Targeting ABCB5 for cancer therapy
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsMarkus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
Claims24
A composition, comprising
- an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence having the following CDRs:
- CDR1-H1:
- SEQ ID NO:3, CDR2-H2:
- SEQ ID NO:4, CDR3-H3:
- SEQ ID NO:5, CDR1-L1:
- SEQ ID NO:6, CDR2-L2:
- SEQ ID NO:7, and CDR3-L3:
- SEQ ID NO:8, wherein the isolated peptide is not mAb 3C2-1D12.
A composition, comprising
- an isolated peptide that selectively binds to ABCB5 comprising at least two antibody variable domains defined by SEQ ID NO:
- 1 and SEQ ID NO:2, wherein the isolated peptide is not mAb 3C2-1D12.
A kit, comprising
- a container housing an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence comprising SEQ ID NO:
- 1 and SEQ ID NO:2, or an amino acid sequence having all of the following CDRs:
- CDR1-H1:
- SEQ ID NO:3, CDR2-H2:
- SEQ ID NO:4, CDR3-H3:
- SEQ ID NO:5, CDR1-L1:
- SEQ ID NO:6, CDR2-L2:
- SEQ ID NO:7, and CDR3-L3:
- SEQ ID NO:8, and instructions for administering the isolated peptide to a human subject.
An anti-ABCB5 antibody or antigen-binding fragment thereof, having at least one human region, wherein the anti-ABCB5 antibody or antigen binding fragment competitively inhibits binding of mAb 3C2-1D12 to ABCB5.
A chimeric antibody comprising a heavy chain and light chain variable domain which specifically binds to ABCB5 and a constant domain, wherein the variable domain and the constant domain are from different species.
Dependencies are inferred from the claim text.